Charnwood Molecular’s work on early stage chemical development for medicinal chemistry projects recently featured in an extensive Chemistry World article, in an interview with Dr David Lathbury.


The divide between contract medicinal chemistry and chemical development needs to be bridged.

That’s the opinion of Dr David Lathbury, who is working with Charnwood Molecular, on its process research and development services for small to mid-sized pharma and biotechnology clients.

The idea is to combine early stage chemical development research with medicinal chemistry projects. By getting chemical development involved earlier, it means the chemistry is better understood before it’s transferred either to another CRO or an in-house team for larger scale production.

‘That way, you have a much better idea of what you’re handing over, and the other side know what they are getting into”, states Dr Lathbury.

The full Chemistry World article, written by Dr Phillip Broadwith, Business Editor of Chemistry World, can be read here: Chemistry World Article.

We’ve now finalised our event schedule through to the end of the year and we have a number of events on the horizon:

Event: The 20th Anniversary UKASF
Date: 7-8 November 2016
Venue: The Imperial War Museum, Duxford, Cambridge, UK

Event: The Chemistry of Collaboration 2016
Date: 8 November 2016
Venue: Alderley Park, Manchester, UK

Event: Antimocrobial Drug Discovery 2016: Plugging the Antibiotics Gap: A Medicinal Chemist’s Perspective
Date: 16 November 2016
Venue: Alderley Park, Manchester, UK

Event: Highlights in Medicinal Chemistry II
Date: 23 November 2016
Venue: London

Event: Recent Disclosures of Clinical Candidates and SMR Award Lecture
Date: 1 December 2016
Venue: NHLI, London

Event: Late Stage Functionalisation for Synthesis and Medicines
Date: 5 December 2016
Venue: Oxford

Should you wish to meet us at any of these, please email us at:

Operating from state-of-the-art research facilities in Loughborough and BioCity, Nottingham, UK, Charnwood Molecular is a leading Contract Research Organisation, providing medicinal, process and synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.

As part of an ongoing expansion to meet the rising demand for our services, we are looking to recruit a number of experienced synthetic and medicinal chemists to join our project teams.

Candidate specification:

Ideally PhD qualified with previous experience of working in the following areas within the biotech or pharmaceutical industry:

• Drug Discovery
• Lead Optimisation
• Process Research and Development

Consideration will also be given to experienced graduate level chemists who have worked within these target industries.
We can offer a competitive salary and benefits, including a company pension scheme.

At Charnwood Molecular we recognise that a company’s real strengths lie in the people that it employs. Our strategy is therefore to employ the most talented chemists to bring a wealth of creative experience to the team, and we look forward to receiving your application.

Call to action:

To be considered for these positions please submit a detailed CV and covering letter to:


We are in the process of putting together our conference and exhibition schedule to the end of this year. So far we have a number of events on the horizon:

Event: The Chemistry of Collaboration 2016
Date: 6 October 2016
Venue: Oxford, UK

Event: ELRIG Drug Discovery 2016
Date: 13-14 October 2016
Venue: Liverpool, UK

Event: LATi 2016 Showcase: From Earth to Space and Beyond
Date: 24 October 2016
Venue: Loughborough University Science and Enterprise Park

Event: The 20th Anniversary UKASF
Date: 7-8 November 2016
Venue: The Imperial War Museum, Duxford, Cambridge, UK

Event: Antimocrobial Drug Discovery 2016: Plugging the Antibiotics Gap: A Medicinal Chemist’s Perspective
Date: 16 November 2016
Venue: Alderley Park, Manchester, UK

Should you wish to meet us at any of these events, please email us at:

As you may know, certainly if you were there, we held a draw on our stand across the three main days of EFMC in Manchester last week to win a range of Charnwood beers.

Charnwood Molecular - François-René Alexandre with his prize.

The winners of the specially selected “Charnwood Brewery” box sets are:

• François-René Alexandre of Idenix, France
• Francis Wilson of Summit, UK
• Hans-Peter Buchstaller of Merck, Germany

Pictured – François-René Alexandre with his prize on the Charnwood Molecular EFMC stand.

We look forward to seeing you at the next event/conference.

Mastering Medicinal Chemistry - Boston

We are in attendance at next month’s Mastering Medicinal Chemistry conference, which takes place this year in Boston, MA, USA.

Charnwood Molecular’s, Business Development Director, Dr Robin Wilkes, will be at the event and should you wish to organise in advance to meet up with him, please email him directly at:

The Mastering Medicinal Chemistry conference is now in its 14th year and remains a well-established and popular annual event for senior-level medicinal chemists. The 2016 program features the hottest topics in medicinal chemistry from leaders in the pharmaceutical, biotech and academic spaces. Through cutting-edge case studies, panel discussions, poster presentations and breakout discussions, we showcase the biggest opportunities for small molecules. Several topics will be given special coverage, including small molecules in immuno-oncology, covalent inhibitors, receptor kinetics, CNS kinases, macrocycles, screening diversity, high-throughput experimentation, and novel targets such as RNA, and transporters.

Charnwood at EFMC 2016

We are exhibiting at the forthcoming XXIV EFMC International Symposium on Medicinal Chemistry.

Charnwood Molecular will be exhibiting on Stand 38 in the main exhibition area.

The event is held from 28th August to 1st September 2016 at the International Conference Centre, Manchester, UK.

EFMC is organised by the Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC).

More details on the event can be found here:

If you would like to visit us at the event, please email us at:

No stranger to the limelight, being the author of our “Views from the Bench – Chemist’s Blog”, Phil Thorne has been involved with the Scientific Laboratory Show’s new campaign to chronicle the ‘History of the Laboratory in Ten Objects’.

Phil points to the mass-production of laboratory glassware as a major turning point in the history of the laboratory.


The top ten nominated objects will go into the Show’s ‘Hall of Fame’ on 25th May, and delegates will be asked to vote for their Number One object during the Show and conference.

Further details are available here:

Dr Robin Wilkes, Business Development Director

Dr Robin Wilkes, Business Development Director

Our Business Development Director, Robin Wilkes, took a look at positive signs for the Drug Discovery industry earlier this year and assembled some of the reasons behind this in an article he put together for a number of news websites. It is reproduced here:-

Seems like we have only just started 2016 but already there’s positive signs in the news for how the Pharmaceutical industry is now addressing the discovery of new medicines…

1. There were 51 New Drug Approvals in 2015, a 66 year high, with nearly 40% of those being ‘first in class’ therapeutics and 60% being small molecules. Perhaps this shows increasing innovation levels in the industry including……

2. The delivery of new technologies such as 3D-printing, from which the first Drug Approval was granted by the FDA in 2015. Spritam® (levetiracetam), for the treatment of epileptic seizures, is the first drug to be manufactured with this technology. Innovation will be further driven by…

3. The availability of new molecular tools, such as CRISPR-Cas9, which edits genes and from which there are positive hopes for the delivery of new therapeutics. There also appears to have been a refocusing of where resources are deployed, for example….

4. The industry appears to have woken up to the important need for new Antibiotics, with new and fairer ways to pay for their development now on the agendas of both Pharma companies and Governments. And…

5. Pharma companies are now also focusing more on Rare or Orphan diseases, defined as those which affect <200K people in USA or <5 in 10K people in Europe. 2016 will see two drugs enter the market for such diseases that have the potential to become ‘blockbusters’, prompting interest beyond niche Biotech companies.


We are in the process of putting together our conference schedule for the next couple of months.

So far we have a couple of events on the horizon:

Event: 27th Symposium on Medicinal Chemistry in Eastern England
Date: 21 April 2016
Venue: Hatfield, UK

Event: Kinase 2016: Next Generation Inhibitors
Date: 16-17 May 2016
Venue: BioCity, Nottingham

Should you wish to meet us at either of these, please email us at: